Holen Sie sich die Stockscreener-App
26.78
0.21%
-0.2095
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Jefferies cuts Mineralys Therapeutics price target on drug concerns - Investing.com
Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS) - Seeking Alpha
Mineralys Therapeutics price target raised to $51 from $46 at BofA - TipRanks
Stifel reiterates Buy rating on Mineralys stock, $52 target - Investing.com
BofA raises Mineralys Therapeutics stock price target on NDA progress - Investing.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2025 Earnings Call Transcript - Insider Monkey
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Insight - GuruFocus
Decoding Mineralys Therapeutics Inc (MLYS): A Strategic SWOT Ins - GuruFocus
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - Bitget
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c) - TipRanks
Mineralys Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Mineralys Therapeutics Q4 2025 beats EPS forecast - Investing.com
Mineralys Therapeutics and Lorundrostat: Clinical Development, Competitive Landscape, and Regulatory Overview for Hypertension Therapy 2122273536 - Minichart
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Mineralys Therapeutics 10-K: $0 Revenue, $(2.29) EPS - TradingView
MINERALYS THERAPEUTICS ($MLYS) Releases Q4 2025 Earnings - Quiver Quantitative
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss - marketscreener.com
Experimental hypertension drug lorundrostat heads for FDA decision in Dec. 2026 - Stock Titan
Mineralys Therapeutics Inc options imply 6.5% move in share price post-earnings - TipRanks
Mineralys Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Mineralys earnings in focus as FDA lorundrostat decision looms By Investing.com - Investing.com Australia
Mineralys earnings in focus as FDA lorundrostat decision looms - Investing.com
How Investors Are Reacting To Mineralys Therapeutics (MLYS) FDA Acceptance Of Lorundrostat Hypertension NDA - simplywall.st
Capital International Investors Sells 505,624 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Barclays PLC Has $24.79 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Atika Capital Management LLC Buys New Shares in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data By Investing.com - Investing.com UK
Mineralys Shares Climb After FDA Accepts NDA for Blood Pressure Medication - Bitget
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat
3 Reasons Not to Sleep on ResMed Stock - AOL.com
H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance - Investing.com UK
Mineralys blood pressure drug under FDA review (MLYS:NASDAQ) - Seeking Alpha
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap DownHere's What Happened - MarketBeat
Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data - Investing.com
H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance By Investing.com - Investing.com Canada
Mineralys (MLYS) Down (-4.6%): Phase 2 Sleep Apnea Trial Fails Primary Endpoint - Trefis
Why Mineralys Therapeutics Stock Is Sinking Today - TipRanks
Mineralys Therapeutics announces FDA acceptance of lorundrostat NDA - TipRanks
Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea - marketscreener.com
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results - Bitget
Mineralys Therapeutics announces FDA acceptance of NDA for lorundrostat for treatment of adults with hypertension and topline Explore-Osa trial results - marketscreener.com
Mineralys Therapeutics Announces FDA Acceptance Of NDA For Lorundrostat For Treatment Of Adults With Hypertension And Topline Explore-Osa Trial Results - TradingView
Mineralys Reports Mixed Phase 2 Results for Lorundrostat - TipRanks
Mineralys Therapeutics Announces FDA Acceptance of NDA for - GlobeNewswire
Mineralys Therapeutics to Announce Fourth Quarter and Full - GlobeNewswire
(MLYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
165,000 Shares in Mineralys Therapeutics, Inc. $MLYS Bought by Rhenman & Partners Asset Management AB - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Stake Boosted by American Century Companies Inc. - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
SR One Capital Management LP Has $80.16 Million Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Vanguard Group Inc. Has $114.48 Million Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 4%Should You Sell? - MarketBeat
A Look At Mineralys Therapeutics (MLYS) Valuation As Lorundrostat Progress Shapes Investor Optimism - Sahm
MLYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Citigroup Inc. - MarketBeat
Chart Watch: Can Mineralys Therapeutics Inc expand its profit marginsJuly 2025 Reactions & Low Drawdown Trading Strategies - baoquankhu1.vn
MLYS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Stock Traders Buy High Volume of Mineralys Therapeutics Call Options (NASDAQ:MLYS) - MarketBeat
Biotech Mineralys gives new hire 27,920 options, 20,940 restricted stock units - Stock Titan
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):